Jade Biosciences reports preclinical data for JADE301 in dermatomyositis; Phase 1 planned Q4 2026
Jade Biosciences announced preclinical data for JADE301, its anti-interferon beta antibody being developed for dermatomyositis, a rare autoimmune disease. The company said the data show high-affinity IFN-ß neutralization, a longer half-life than a dazukibart comparator, and good nonclinical tolerability, and it expects to start a Phase 1 trial in the fourth quarter of 2026.
Key points
- JADE301 binds IFN-ß with a K D of 11.3 pM, about 2.5-fold higher affinity than the dazukibart comparator.
- Non-human primate half-life is about 30 days after IV dosing, roughly 3-fold longer than the comparator.
- Planned placebo-controlled Phase 1 trial in 24 healthy volunteers to start in Q4 2026, with interim data expected in the second half of 2027.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 30, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.